Lacosamide "1a Farma" (Lacosamide)

Lacosamide is an antiepileptic drug indicated for the management of focal seizure disorders. It is used as an adjunctive or monotherapy option to improve seizure control.

• Partial‑onset seizures (epilepsy): reduces seizure frequency when added to existing therapy.
• Adjunctive therapy for focal seizures: enhances overall seizure control in patients not fully controlled by other agents.
• Monotherapy for partial‑onset seizures: may be initiated as first‑line treatment in appropriate patients.

• Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, which stabilizes hyperexcitable neuronal membranes and diminishes the repetitive neuronal firing that underlies seizure activity. By selectively targeting the sodium channel's slow inactivation phase, it reduces the propagation of epileptiform discharges without markedly affecting normal neuronal conduction.

Lacosamide may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Nausea: mild to moderate upset stomach.
• Headache: tension‑type or throbbing pain.
• Fatigue: increased tiredness or lack of energy.
• Vision disturbances: blurred or double vision.
• Tremor: involuntary shaking of limbs.

Serious or Rare Side Effects

• Cardiac arrhythmia: abnormal heart rhythm, including PR‑interval prolongation.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Suicidal thoughts: emergence of depressive symptoms or suicidal ideation.
• Hypersensitivity: rash, itching, or swelling of face and throat.
• Liver enzyme elevation: significant increase in hepatic transaminases.
• Blood dyscrasias: rare cases of agranulocytosis or pancytopenia.

Before initiating therapy, clinicians should evaluate patient history and monitor for potential risks.

• Cardiac assessment: obtain baseline ECG in patients with known heart disease.
• Renal function: adjust monitoring in patients with impaired renal clearance.
• Hepatic function: evaluate liver enzymes periodically.
• Pregnancy and lactation: discuss unknown safety profile with women of childbearing potential.
• Concomitant CNS depressants: use caution when combined with other sedating agents.
• Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Lacosamide can interact with several medications, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce lacosamide plasma levels.
• Concomitant use with other sodium‑channel blockers (e.g., lamotrigine, topiramate): increased risk of cardiac conduction abnormalities.

Moderate Interactions (Monitor Closely)

• Alcohol: may enhance central nervous system depression.
• Opioids: additive sedative effects require dose adjustments.
• Anticoagulants (e.g., warfarin): monitor INR for potential changes.
• Antidepressants (e.g., SSRIs): watch for heightened dizziness or somnolence.
• Diuretics: assess electrolyte balance, especially potassium.